{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:02:48Z","timestamp":1790834568018,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Center for AIDS Research, Wuhan University","award":["PTPP2023002"],"award-info":[{"award-number":["PTPP2023002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80749-9","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T13:39:09Z","timestamp":1733405949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China"],"prefix":"10.1038","volume":"14","author":[{"given":"Yu","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingzheng","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"issue":"1","key":"80749_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11904-019-00478-x","volume":"17","author":"W Cao","year":"2020","unstructured":"Cao, W., Hsieh, E. & Li, T. Optimizing treatment for adults with HIV\/AIDS in China: Successes over two decades and remaining challenges. Curr. HIV\/AIDS Rep. 17 (1), 26\u201334 (2020).","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"11","key":"80749_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan, R. & Uldrick, T. S. HIV-associated cancers and related diseases. N Engl. J. Med. 378 (11), 1029\u20131041 (2018).","journal-title":"N Engl. J. Med."},{"issue":"7","key":"80749_CR3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood.2020005469","volume":"139","author":"A Carbone","year":"2022","unstructured":"Carbone, A., Vaccher, E. & Gloghini, A. Hematologic cancers in individuals infected by HIV. Blood 139 (7), 995\u20131012 (2022).","journal-title":"Blood"},{"issue":"4","key":"80749_CR4","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S2352-3018(19)30039-6","volume":"6","author":"DM Aboulafia","year":"2019","unstructured":"Aboulafia, D. M. Non-Hodgkin lymphoma in people with HIV. Lancet HIV. 6 (4), e209\u2013e210 (2019).","journal-title":"Lancet HIV"},{"issue":"1","key":"80749_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/COH.0000000000000334","volume":"12","author":"\u00c1H Borges","year":"2017","unstructured":"Borges, \u00c1. H. Combination antiretroviral therapy and cancer risk. Curr. Opin. HIV AIDS. 12 (1), 12\u201319 (2017).","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"11","key":"80749_CR6","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","volume":"4","author":"RU Hern\u00e1ndez-Ram\u00edrez","year":"2017","unstructured":"Hern\u00e1ndez-Ram\u00edrez, R. U., Shiels, M. S., Dubrow, R. & Engels, E. A. Cancer risk in HIV-infected people in the USA from 1996 to 2012: A population-based, registry-linkage study. Lancet HIV. 4 (11), e495\u2013e504 (2017).","journal-title":"Lancet HIV"},{"issue":"18","key":"80749_CR7","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1097\/QAD.0000000000002003","volume":"32","author":"AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord","year":"2018","unstructured":"AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord. Non-hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32 (18), 2777\u20132786 (2018).","journal-title":"AIDS"},{"key":"80749_CR8","doi-asserted-by":"publisher","first-page":"798008","DOI":"10.3389\/fonc.2021.798008","volume":"11","author":"C Wang","year":"2022","unstructured":"Wang, C., Liu, J. & Liu, Y. Progress in the treatment of HIV-associated lymphoma when combined with the antiretroviral therapies. Front. Oncol. 11, 798008 (2022).","journal-title":"Front. Oncol."},{"key":"80749_CR9","doi-asserted-by":"publisher","first-page":"1153790","DOI":"10.3389\/fimmu.2023.1153790","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: The Central and Western China AIDS Lymphoma League 001 study (CALL-001 study). Front. Immunol. 14, 1153790 (2023).","journal-title":"Front. Immunol."},{"issue":"19","key":"80749_CR10","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1111\/jcmm.17534","volume":"26","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China. J. Cell. Mol. Med. 26 (19), 5067\u20135077 (2022).","journal-title":"J. Cell. Mol. Med."},{"issue":"16","key":"80749_CR11","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1002\/cncr.26723","volume":"118","author":"SK Barta","year":"2012","unstructured":"Barta, S. K., Lee, J. Y., Kaplan, L. D., Noy, A. & Sparano, J. A. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 118 (16), 3977\u20133983 (2012).","journal-title":"Cancer"},{"issue":"19","key":"80749_CR12","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","volume":"122","author":"SK Barta","year":"2013","unstructured":"Barta, S. K. et al. Treatment factors affecting outcomes in HIV-associated non-hodgkin lymphomas: A pooled analysis of 1546 patients. Blood 122 (19), 3251\u20133262 (2013).","journal-title":"Blood"},{"issue":"5","key":"80749_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.18704","volume":"201","author":"KJC Lim","year":"2023","unstructured":"Lim, K. J. C. et al. Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. Br. J. Haematol. 201 (5), 865\u2013873 (2023).","journal-title":"Br. J. Haematol."},{"issue":"3","key":"80749_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00277-020-03908-8","volume":"99","author":"J Opie","year":"2020","unstructured":"Opie, J., Antel, K., Koller, A. & Novitzky, N. In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes. Ann. Hematol. 99 (3), 571\u2013578 (2020).","journal-title":"Ann. Hematol."},{"issue":"14","key":"80749_CR15","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1182\/bloodadvances.2021004458","volume":"5","author":"JP Alderuccio","year":"2021","unstructured":"Alderuccio, J. P. et al. HIV-associated Burkitt lymphoma: Outcomes from a US-UK collaborative analysis. Blood Adv. 5 (14), 2852\u20132862 (2021).","journal-title":"Blood Adv."},{"issue":"22","key":"80749_CR16","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.20.00303","volume":"38","author":"M Roschewski","year":"2020","unstructured":"Roschewski, M. et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J. Clin. Oncol. 38 (22), 2519\u20132529 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"80749_CR17","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","volume":"105","author":"M Spina","year":"2005","unstructured":"Spina, M. et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials. Blood 105 (5), 1891\u20131897 (2005).","journal-title":"Blood"},{"issue":"5","key":"80749_CR18","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","volume":"106","author":"LD Kaplan","year":"2005","unstructured":"Kaplan, L. D. et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106 (5), 1538\u20131543 (2005).","journal-title":"Blood"},{"issue":"1","key":"80749_CR19","doi-asserted-by":"publisher","first-page":"8321","DOI":"10.1038\/s41598-018-26743-4","volume":"8","author":"KC Wei","year":"2018","unstructured":"Wei, K. C. et al. Pneumocystis Jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients. Sci. Rep. 8 (1), 8321 (2018).","journal-title":"Sci. Rep."},{"issue":"17","key":"80749_CR20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","volume":"134","author":"A Noy","year":"2019","unstructured":"Noy, A. Optimizing treatment of HIV-associated lymphoma. Blood 134 (17), 1385\u20131394 (2019).","journal-title":"Blood"},{"issue":"3","key":"80749_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (3), 205\u2013216 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"80749_CR22","doi-asserted-by":"crossref","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32 (27), 3059\u20133067 (2014) (European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea; German High-Grade Lymphoma Study GroupNCIC Clinical Trials Group; Nordic Lymphoma Study Group).","DOI":"10.1200\/JCO.2013.54.8800"},{"issue":"5","key":"80749_CR23","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn, L. H. et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109 (5), 1857\u20131861 (2007).","journal-title":"Blood"},{"issue":"10","key":"80749_CR24","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1200\/JCO.20.03288","volume":"39","author":"AJ Olszewski","year":"2021","unstructured":"Olszewski, A. J. et al. Burkitt lymphoma international prognostic index. J. Clin. Oncol. 39 (10), 1129\u20131138 (2021).","journal-title":"J. Clin. Oncol."},{"key":"80749_CR25","doi-asserted-by":"publisher","first-page":"1248790","DOI":"10.3389\/fonc.2023.1248790","volume":"13","author":"Y Xiong","year":"2023","unstructured":"Xiong, Y. et al. The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV\/AIDS in China. Front. Oncol. 13, 1248790 (2023).","journal-title":"Front. Oncol."},{"key":"80749_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-143253","volume":"136","author":"T Magnusson","year":"2020","unstructured":"Magnusson, T. et al. Clinical features, treatments and outcomes of HIV associated diffuse large B-cell lymphoma: A single-center experience. Blood 136, 20 (2020).","journal-title":"Blood"},{"issue":"6","key":"80749_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/bjh.13221","volume":"168","author":"P Schommers","year":"2015","unstructured":"Schommers, P. et al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV lymphoma cohort. Br. J. Haematol. 168 (6), 806\u2013810 (2015).","journal-title":"Br. J. Haematol."},{"issue":"18","key":"80749_CR28","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","volume":"31","author":"C Besson","year":"2017","unstructured":"Besson, C. et al. ANRS-CO16 LYMPHOVIR Cohort. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. AIDS 31 (18), 2493\u20132501 (2017).","journal-title":"AIDS"},{"issue":"5","key":"80749_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/QAD.0000000000000133","volume":"28","author":"R Coutinho","year":"2014","unstructured":"Coutinho, R. et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS 28 (5), 689\u2013697 (2014).","journal-title":"AIDS"},{"issue":"3","key":"80749_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1182\/blood.2020006926","volume":"137","author":"AM Evens","year":"2021","unstructured":"Evens, A. M. et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 137 (3), 374\u2013386 (2021).","journal-title":"Blood"},{"issue":"3","key":"80749_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3324\/haematol.2019.243386","volume":"106","author":"JA Sparano","year":"2021","unstructured":"Sparano, J. A. et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin\u2019s lymphoma. Haematologica 106 (3), 730\u2013735 (2021).","journal-title":"Haematologica"},{"issue":"11","key":"80749_CR32","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","volume":"99","author":"SK Barta","year":"2014","unstructured":"Barta, S. K. et al. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica 99 (11), 1731\u20131737 (2014).","journal-title":"Haematologica"},{"issue":"8","key":"80749_CR33","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2352-3026(20)30126-5","volume":"7","author":"SA Atallah-Yunes","year":"2020","unstructured":"Atallah-Yunes, S. A., Murphy, D. J. & Noy, A. HIV-associated Burkitt lymphoma. Lancet Haematol. 7 (8), e594\u2013e600 (2020).","journal-title":"Lancet Haematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80749-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80749-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80749-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:04:29Z","timestamp":1733407469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80749-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80749"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80749-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4429234\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30397"}}